Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 501–600 of 739
Chazova, I. E., & Martynyuk, T. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.03.000185 · Cited by 3
The Pursuit of Risk Assessment and Stratification Tools in Pulmonary Arterial Hypertension
Ford, H. J., & LeVarge, B. L. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.10.026 · Cited by 3
Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?
Singh, N., & Ventetuolo, C. E. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0040ed · Cited by 3
“More granular discrimination within intermediate-risk PAH is needed, as this group represents a significant proportion of prevalent patients; as much as 70% in some cohorts (13).”
BackgroundJiang, H., Tan, J. L., Ruan, W., Hon, J. S., Ismail, A. B., Lim, C. L., Perumal, S., Koh, M., Sewa, D. W., Phua, G. C., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.70032 · Cited by 2
Guo, X., Qian, J., Lai, J., Wang, H., Tian, Z., Wang, Q., Zhao, J., Zeng, X., Li, M., & Liu, Y. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004010 · Cited by 2
Orozco‐Levi, M., Villegas, A. L., Camacho, R. E. C., Pacheco, M., Cortes-Colorado, J., Franco, C. J. V., Gómez-Paláu, R., de Arco, L. T. F., Luque, J. D., Pérez-Zauner, A. M., et al. (2025) · Critical Care Science · doi:10.62675/2965-2774.20250182 · Cited by 3
Dardi, F., Donato, F., Cennerazzo, F., Niro, F., Ballerini, A., Guarino, D., Russo, V. C., Bertozzi, R., Nardi, E., Manes, A., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106939 · Cited by 2
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension
Liu, C., Qiu, B., Li, S.-P., Ma, J.-S., Liu, M. D. H., Zhang, S.-J., Zhu, X.-J., Yang, Y.-J., Lian, T., Cheng, Y.-Y., et al. (2026) · European Respiratory Journal · doi:10.1183/13993003.02367-2025 · Cited by 2
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.02.035 · Cited by 2
Balmori, G. T., Alania-Torres, E., Pichardo, Y. M. R., Cruz‐Utrilla, A., & Muñoz, A. V. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.108164 · Cited by 2
Amado, V. M., Pereira, M. F., Correa3, R. A., Campos, F. T. A. F., Fernandes, C. J. C. D. S., Ferreira, E. V. M., Gazzana, M. B., Rocha, M. J. J., Jardim, C., Alves-Jr1, J. L., et al. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250528 · Cited by 2
“…was proposed by a Swedish group (58) and reproduced by the analysis of the European registry (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension—COMPERA), (59) considering the classification of the different parameters into the three risk ranges (Table 4).”
Tools of the Trade: How Do You Perform and Interpret an Exercise Test?
Rischard, F. P., & Borlaug, B. A. (2019) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-18.2.47 · Cited by 2
Experience with Selexipag to Treat Pulmonary Arterial Hypertension
Karelkina, E. V., Goncharova, N. S., Simakova, M. A., & Моисеева, О. М. (2020) · Kardiologiia · doi:10.18087/cardio.2020.4.n1026 · Cited by 2
Camacho, R. E. C., Orozco‐Levi, M., Londoño, A., Acosta, D. F., Alvarado, J. J., Carvajal, J. F., Camargo-Mendoza, J. P., Gómez-Paláu, R., Martínez-Ramírez, I. J., Méndez, J., et al. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.22000022 · Cited by 2
Lu, W., Xu, J., Chen, Y., Huang, J., Shen, Q., Sun, F., Zhang, Y., Ji, D.-J., Xue, B., & Li, J. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112303 · Cited by 2
Kamp, J. C., Fuge, J., Karsten, J., Rümke, S., Hoeper, M. M., Park, D., Kühn, C., & Olsson, K. M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01541-3 · Cited by 2
“Risk at baseline and follow-up was calculated according to current recommendations [16].”
MethodSelf-citationPark, D., Meltendorf, T., Kahl, K. G., Kamp, J. C., Richter, M. J., Gall, H. J., Ghofrani, H. A., Hoeper, M. M., Olsson, K. M., & Fuge, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812862 · Cited by 2
“Clinical signs of right heart failure, 6MWD, NT-proBNP/BNP, and WHO FC are strong indicators of disease severity and risk status in patients with PAH (23).”
BackgroundMethodInfluentialSelf-citationStubbe, B., Halank, M., Seyfarth, H., Obst, A., Desole, S., Opitz, C. F., & Ewert, R. (2022) · Pneumologie · doi:10.1055/a-1740-3377 · Cited by 2
Self-citationGibbs, J. S. R. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198766223.003.0034 · Cited by 2
Self-citationLi, X., Duan, A., Jin, Q., Zhang, Y., Luo, Q., Zhao, Q., Yan, L., Huang, Z., Hu, M., Xiong, C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14154 · Cited by 2
“Finally, the risk group was determined using the aforementioned integers.(20)”
MethodIncorporation of noninvasive assessments in risk prediction for pulmonary arterial hypertension
Quan, R., Chen, X., Yang, T., Li, W., Qian, Y., Lin, Y., Xiong, C., Shan, G., Gu, Q., & He, J. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12158 · Cited by 2
Ahmadzadeh, A., Sheibani, M., Farsad, F., Dehghan, P., Gachkar, L., & Nazarpoor, S. (2023) · Immunopathologia Persa · doi:10.34172/ipp.2023.34435 · Cited by 2
“The time between the development of symptoms and the identification of PAH is 2-4 years, therefore making its diagnosis as soon as when the symptoms appear (11-14).”
BackgroundSurgery and Anesthesia in Patients with Pulmonary Hypertension
Condliffe, R. A., Newton, R., Bauchmüller, K., Bonnett, T. J., Kerry, R. M., Mannings, A., Nair, A., Selby, K., Skinner, P. P., Wilson, V. J., et al. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1772753 · Cited by 2
Pulmonale Hypertonie assoziiert mit Linksherzerkrankungen (Gruppe 2)
Schmidt, K. H., Bikou, O., Blindt, R., Bruch, L., Felgendreher, R., Hohenforst‐Schmidt, W., Holt, S., Ladage, D., Pfeuffer-Jovic, E., Rieth, A. J., et al. (2023) · Pneumologie · doi:10.1055/a-2145-4792 · Cited by 2
Oba, Y., Goite, Y., Maduke, T., & Fakhouri, E. W. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015824 · Cited by 2
Pediatric pulmonary arterial hypertension; is it possible to predict its outcome?
Agha, H. M., Hegazy, R., Gamal, A., Essam, R., Elmessih, A. A., Behairy, A., Dahdah, N., Abdelwahed, A. S. K., Sobhy, N., & Ali, N. (2025) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1398 · Cited by 2
“…C LE children, as in adults, clinical risk strati fi cation tools composed of various clinical and biochemical variables (including NT pro-BNP) as proposed in guidelines based on expert opinion are of clinical value in risk strati fi cation and prognostication both at diagnosis and at follow-up [33].”
RPL39 Was Associated With Sex Differences in Pulmonary Arterial Hypertension
Wang, H., Li, L., Zhou, G., Wang, L., & Wu, Z. (2025) · Canadian Respiratory Journal · doi:10.1155/carj/7139235 · Cited by 2
“Pulmonary arterial hypertension (PAH) is a severe disease that can lead to right heart failure and even death [1, 2].”
Rosenkranz, S., Ghofrani, H. A., & Hoeper, M. M. (2017) · Der Klinikarzt · doi:10.1055/s-0043-116604 · Cited by 2
“[10] Hoeper MM, Kramer T, Pan Z, et al.”
Self-citationUpdates in pulmonary hypertension and other pulmonary vascular diseases
Bernardo, R. J., Bokan, A., & Ramjug, S. (2019) · Breathe · doi:10.1183/20734735.0187-2019 · Cited by 2
“7% for patients who were initially considered low-risk but moved to an intermediate-risk category on follow-up [8].”
BackgroundTreatment Considerations for Pulmonary Arterial Hypertension and Assessment of Treatment Response
Frantz, R. P. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-16.3.120 · Cited by 2
A Retrospective Study of Suicide Attempts in Patients With Pulmonary Hypertension
Hu, W., & Lin, C. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.02.005 · Cited by 2
Corris, P. A. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.9 · Cited by 2
TAPSE/sPAP predicts the long-term prognosis in pulmonary arterial hypertension patients
Uygur, B., Yıldız, M., Demir, A. R., Kahraman, S., Sancar, K. M., Uykusavas, A., Ağuş, H. Z., Güner, A., Çelik, Ö., & Ertürk, M. (2021) · Koşuyolu Heart Journal · doi:10.51645/khj.2021.m64 · Cited by 2
“The latest guideline and three registries which were released after the guideline highlighted the importance of frequent risk assessment and achieving the low risk status(1,15-17).”
BackgroundMa, R., Han, P.-P., Tao, X., Li, H., Wang, L., Zhai, Z.-G., & Fu, L. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s335051 · Cited by 2
Pulmonary arterial hypertension: challenges and achievements 2021
Rezukhina, E. A., Martynyuk, T. V., Солтановна, В. З., Владимирович, Г. В., & Чазова, И. Е. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-80-89 · Cited by 2
“Категория риска годичной смертности (низкий, промежуточный, высокий риск) оценивается по шкале COMPERA на основании наличия ≥2 исходных показателей (ФК (ВОЗ), дистанция в Т6МХ, уровни BNP/NT-proBNP, данные КПОС – среднее ДПП, СИ и/или SvO2).”
InfluentialA Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension
Nafees, B., de Freitas, H. M., Beaudet, A., Todd, E., & Gin‐Sing, W. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s400061 · Cited by 2
D’Alto, M., Badagliacca, R., Airò, E., Ameri, P., Argiento, P., Garascia, A., Lombardi, C., Mulè, M., Raineri, C., Scelsi, L., et al. (2024) · Vascular Pharmacology · doi:10.1016/j.vph.2024.107374 · Cited by 2
Self-citationPulmonary hypertension and the potential of ‘drug’ repurposing: A case for African medicinal plants
Jacobs, S., Payne, C., Shaboodien, S., Kgatla, T., Pretorius, A., Jumaar, C., Maarman, G. J., & Sanni, O. (2024) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2024.v30i2.1352 · Cited by 2
“[18] Great strides have therefore been made with regard to PH treatment, but there is room for improvement, as despite these drugs, patients still die from PH.”
Dong, W., Hong, Z., Wang, A., Jiang, K., Hai, Z., Fu, Z., Guo, Z., Su, H., & Cao, Y. (2024) · Congenital Heart Disease · doi:10.32604/chd.2024.052267 · Cited by 2
Tamura, Y., Hosokawa, K., Horimoto, K., Ikeda, S., Inami, T., Kubota, K., Nakanishi, N., Shirai, Y., Tanabe, N., Tsujino, I., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14232656 · Cited by 2
“However, the implementation of guideline-recommended therapies for PAH remains suboptimal, leading to disparities in clinical outcomes across different regions and healthcare settings [3,4].”
Zhou, J., Wong, K. H. G., Lee, S., Liu, T., Leung, K. S. K., Jeevaratnam, K., Cheung, B. M. Y., Wong, I. C. K., Zhang, Q., & Tse, G. (2021) · medRxiv · doi:10.1101/2021.01.16.21249934 · Cited by 2
Denton, C. P., & Spierings, J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41670 · Cited by 2
“Of these registries, some include all forms of PH (3,4), whereas others focus on PAH of”
BackgroundUlrich, S., & Grünig, E. (2021) · European Respiratory Journal · doi:10.1183/13993003.04376-2020 · Cited by 2
“Thus, taking into account patients’ self-reported perception of HRQoL is of high value for care providers in the risk assessment of patients with PAH and may be of especially high value to stratify the large group of patients assigned to the intermediate risk group according to current guidelines.(15,26) Listening to…”
BackgroundSelf-citationZhai, Y., Li, A., Tao, X., Gao, Q., Xie, W., Zhang, Y., Chen, A., Wang, C., Lei, J., Ding, S., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04053-0 · Cited by 1
Chen, M., Wan, C.-X., Tong, J., Wang, A., Ruan, B., & Shen, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247855 · Cited by 1
Rochmat, M. B., Setianto, B. Y., Anggrahini, D. W., Dinarti, L. K., & Hartopo, A. B. (2025) · Indonesian Journal of Cardiology · doi:10.30701/ijc.1623 · Cited by 1
Assessment of Serum suPAR Levels in Patients with Group 1 and Group 4 Pulmonary Hypertension
Tunçez, A., Yalçın, M. U., Tezcan, H., Altunkeser, B. B., Öztürk, B., Aydoğan, C., Toprak, A. M., Polat, O. C., Aygül, N., Demır, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134671 · Cited by 1
Ashur, A., Levy, A., Liel‐Cohen, N., Sergienko, R., & Kobal, S. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145044 · Cited by 1
“Importantly, several effective therapies are now available for specific forms of PHT, emphasizing the need for early recognition and diagnosis [7,8].”
Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension
Hjalmarsson, C., Thakur, T., Rådegran, G., Björklund, E., Wåhlander, H., Nisell, M., Papageorgiou, J., Söderberg, S., Lautsch, D., & Kjellström, B. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70132 · Cited by 1
Torun, E. G., Özdemiroğlu, N., Bağrul, D., & Ece, İ. (2025) · Pediatric Cardiology · doi:10.1007/s00246-025-03970-x · Cited by 1
Sitbon, O., Ágoston, G., Badagliacca, R., Bálint, O. H., Blanco, I., Coman, I. M., Ewert, R., Halank, M., Jansa, P., Kopeć, G., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00458-2025 · Cited by 1
Self-citationKiyota, T. A., Mendes, P., & Pereira, M. C. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2601388 · Cited by 1
Tsai, T.-H., Ho, W.-J., Wang, C., Lin, C.-P., Hsiao, F., Chan, C.-C., & Chang, C.-Y. (2026) · PubMed · doi:10.6515/acs.202601_42(1).20250818f · Cited by 1
Qin, X., Zheng, L., Zhao, H., Li, Q., Wang, Y., Lu, Q., Chen, P., Xue, Z., & Dong, Z. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1704427 · Cited by 1
“The group 2 PH accounts for approximately half of all cases of PH (3).”
Sotatercept in Children with Pulmonary Hypertension—A Narrative Review
Schulz, J., Stark, V. C., Harbaum, L., Kozlik-Feldmann, R., Mir, T. S., Stute, F., & Olfe, J. (2026) · Children · doi:10.3390/children13040465 · Cited by 1
Tian, H., Wu, Q., Wang, Z., Zhang, Z., Yan, Y. J., Deng, Y., Du, Y., Yang, Z., Li, D., & Yang, F. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.03.025 · Cited by 1
Bousseau, S., Gu, S., & Lahm, T. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.126.322096 · Cited by 1
Kaymaz, C., Kültürsay, B., Tokgöz, H. C., Tanyeri, S., Buluş, Ç., Keskin, B., Çağlıyan, Ç. E., Kibar, M., Erdem, C., Vezir, A., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70362 · Cited by 1
“…(COMPERA) registry and COMPERA 2.0 four‐strata, and the French Pulmonary Hypertension Network (FPHN) registry low‐ risk models, as well as the The Registry to Evaluate Early and Long‐Term PAH Disease Management (REVEAL), REVEAL 2.0 and its abridged 6‐component REVEAL Lite 2.0 scores [26–34].”
InfluentialWaligóra, M., Kurzyna, M., Mularek‐Kubzdela, T., Skoczylas, I., Chrzanowski, Ł., Błaszczak, P., Jaguszewski, M., Kuśmierczyk, B., Ptaszyńska‐Kopczyńska, K., Grześk, G., et al. (2026) · Kardiologia Polska · doi:10.33963/v.phj.114700 · Cited by 1
Lessons from pulmonary hypertension registries
Humbert, M. J. C. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2018.08.003 · Cited by 1
The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis
Mathai, S. C., & Sitbon, O. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_29 · Cited by 1
Stratégies thérapeutiques dans l’hypertension pulmonaire : peut-on encore faire mieux ?
Boucly, A. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30058-2 · Cited by 1
Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options
Francis, L. R., Whitener, S. K., McKinnon, J. S., & Whitener, G. B. (2019) · Current anesthesiology reports · doi:10.1007/s40140-019-00360-x · Cited by 1
Ask the Expert: A Regulatory Perspective on Clinical Trials for Pulmonary Arterial Hypertension
Garnett, C. E., & Stockbridge, N. (2020) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-19.2.62 · Cited by 1
Hipertensión Pulmonar: estratificación de riesgo. Impacto de su reducción en el pronóstico
Gregorietti, V. (2021) · Revista de la Federación Argentina de Cardiología · doi:10.63600/e1dwj907 · Cited by 1
Autoimmune Hemolytic Anemia Causing Group 5 Pulmonary Hypertension: A Rare Case
Karimullah, M. D. H., & Ardining, H. (2020) · Heart Science Journal · doi:10.21776/ub.hsj.2020.001.03.7 · Cited by 1
Leuchte, H. H., Halank, M., Held, M., Borst, M. M., Ewert, R., Klose, H. F. E., Lange, T. J., Meyer, F. J., Skowasch, D., Wilkens, H., et al. (2021) · Pneumologie · doi:10.1055/a-1204-3248 · Cited by 1
Yoshida, M., Adachi, S., Imai, R., Shimokata, S., Nakano, Y., Murohara, T., & Kondo, T. (2021) · PubMed Central · doi:10.18999/nagjms.83.2.321 · Cited by 1
Sert, S. M., Asarcıklı, L. D., Esen, A. M., Ösken, A., Şimşek, B., Yağmur, A., Güngör, B., & Yıldırımtürk, Ö. (2021) · Sakarya Medical Journal · doi:10.31832/smj.915463 · Cited by 1
Castaño-Cifuentes, O., Clavijo-Moldón, A. A., & Díaz-Betancur, J. S. (2021) · Archivos de cardiología de México · doi:10.24875/acm.20000528 · Cited by 1
Gaps of evidence in pulmonary arterial hypertension
Vizza, C. D., Ghio, S., Badagliacca, R., Manzi, G., Scelsi, L., Argiento, P., & D’Alto, M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.026 · Cited by 1
Self-citationHemodynamics of Treprostinil Inhalation Solution and Treprostinil Inhalation Powder
El‐Kersh, K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001533 · Cited by 1
Expert provider survey of longitudinal assessment in patients with pulmonary arterial hypertension
Kingrey, J. F., Zhou, C. Y., Dalal, B., & Elwing, J. (2022) · Heart & Lung · doi:10.1016/j.hrtlng.2022.10.016 · Cited by 1
Transplantation pulmonaire pour hypertension pulmonaire sévère
Pavec, J. L., Savale, L., Prévôt, G., Montani, D., Sitbon, O., Fadel, É., Humbert, M. J. C., & Mercier, O. M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.010 · Cited by 1
Stanković, I., Grujičić, K., Cerović, M., Vranić, I., Gaković, B., Panić, M., Cvjetan, R., Zlatković, M., Raspopović, S., & Nešković, A. (2023) · Medicinska istrazivanja · doi:10.5937/medi56-42864 · Cited by 1
“While echocardiography and other cardiac imaging modalities play an important role in the follow-up of patients with precapillary PH, several studies have identified World Health Organization’s functional class (WHO FC), 6-minute walk distance (6MWD), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)…”
BackgroundAlves-Jr, J. L., Costa, E. L. V., Hoette, S., Fernandes, C. J. C. D. S., Ribeiro, H. B., Abizaid, A., Castro, M. A., Piloto, B. M., Lemos, P. A., Jardim, C., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.01.018 · Cited by 1
Risk stratification in Eisenmenger syndrome
Valdeolmillos, E., Boucly, A., Humbert, M. J. C., Sitbon, O., Savale, L., Montani, D., Pavec, J. L., Fadel, É., Ladouceur, M., Fournier, E., et al. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.02.010 · Cited by 1
Mombeini, H., Jani, V., Malhi, J. K., Osgueritchian, R., Goldin, G., Wang, K., Naranjo, M., Mercurio, V., Hassan, H., Hsu, S. S., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102080 · Cited by 1
Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension
Alves-Jr, J. L., & Souza, R. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.02.005 · Cited by 1
Diffusion capacity of the lung—a disease biomarker linking ventilation and circulation
Shafran, I. H., & Lang, I. M. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.11.008 · Cited by 1
Risk stratification methods and their significance in pulmonary arterial hypertension
Avdeev, S. N., & Tsareva, N. A. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.09.000192 · Cited by 1
“Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS).”
InfluentialShould oral combination therapy be the standard of care for pulmonary arterial hypertension?
Ogawa, A., & Matsubara, H. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1722641 · Cited by 1
Sofianopoulou, E., Church, C., Coghlan, G., Howard, L., Johnson, M., Kiely, D. G., Lawrie, A., Lordan, J. L., Wilkins, M. R., Wort, S. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02334-2019 · Cited by 1
Marinescu, D.-C., Christiansen, D. L., Thenganatt, J., & Granton, J. T. (2021) · Research Square · doi:10.21203/rs.3.rs-431468/v1 · Cited by 1
Liu, R., Zheng, Z., He, C., Lei, C., Chen, Y., Fang, Z., Zhang, H., Lu, Z., Nie, H., Liang, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-889429/v1 · Cited by 1
Huang, Z., Yan, L., Zhao, Z., Zhao, Q., Tang, Y., Jin, Q., Zhang, Y., Li, X., Duan, A., Hu, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1321407/v1 · Cited by 1
“0 [15] and ESC/ERS risk strati cation tools [16], and current guidelines recommend assessing exercise tolerance for decision-making [1, 17].”
BackgroundAdachi, S., Nakano, Y., & Furusawa, K. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0145 · Cited by 1
Dean, B. B., Saundankar, V., Stafkey-Mailey, D., Anguiano, R. H., Nelsen, A. C., Gordon, K., & Classi, P. M. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00198-4 · Cited by 1
Estrada, R. A., & Sahay, S. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12252 · Cited by 1
Molecular directors: non-coding RNA and extracellular vehicle in right ventricle remodeling
Kocken, J. M. M. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240516jk · Cited by 1
Hypertension artérielle pulmonaire idiopathique et états apparentés
Canuet, M., Chaouat, A., & Weitzenblum, E. (2015)
Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension
Subías, P. E., & Quezada-Loaiza, C. A. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.12.007
Nowak, A., Bula, K., Głowacki, K., Gawin, W., Kalita, M., Nechoritis, K., Grabka, M., & Mizia‐Stec, K. (2018) · Journal of Rare Cardiovascular Diseases · doi:10.20418/jrcd.vol3no6.316
“lished studies suggest that escalation of PAH treatment should be provided in the first 4–6 months of therapy [3, 4, 5].”
BackgroundPulmonary hypertension: the state of the art
Dimopoulos, K., & Favoccia, C. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.2018.1067
Fanjul, F. J., Abad, G. S., & Jaume, M. R. (2018) · Medicina balear · doi:10.3306/medicinabalear.33.02.11
Manejo de la hipertensión arterial pulmonar: estratificación pronóstica y opciones terapéuticas
Loaiza, C. A. Q. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Constantine, A. H., Tulloh, R. M. R., Condliffe, R. A., Clift, P., & Dimopoulos, K. (2019) · Pulmonary Circulation · doi:10.1177/2045894019882627
Malaspinas, I. (2019) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:123504
Co istotnego zapamiętamy z nowości kończącego się roku w nadciśnieniu płucnym?
Lewicka, E. (2019) · Choroby Serca i Naczyń · doi:10.5603/chsin.2019.0006
Risk Stratification—What's My Risk? A Practitioner's Tool
Preston, I. R. (2019) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-18.3.84
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.